ANC 0 3 0 3 B-clinical_variable
> 4 5 4 5 O
1500 6 10 6 10 B-lower_bound
/ 10 11 10 11 I-lower_bound
mm3 11 14 11 14 I-lower_bound

Acute 0 5 15 20 O
or 6 8 21 23 O
chronic 9 16 24 31 O
impairment 17 27 32 42 O
( 28 29 43 44 O
other 29 34 44 49 O
than 35 39 50 54 O
dyspnea 40 47 55 62 B-chronic_disease
) 47 48 62 63 O
limiting 49 57 64 72 O
the 58 61 73 76 O
ability 62 69 77 84 O
to 70 72 85 87 O
comply 73 79 88 94 O
with 80 84 95 99 O
study 85 90 100 105 O
requirements 91 103 106 118 O
( 104 105 119 120 O
eg 105 107 120 122 O
, 107 108 122 123 O
pulmonary 109 118 124 133 O
function 119 127 134 142 O
tests 128 133 143 148 O
) 133 134 148 149 O

Adult 0 5 150 155 O
male 6 10 156 160 B-gender

Aspartate 0 9 161 170 B-clinical_variable
aminotransferase 10 26 171 187 I-clinical_variable
( 27 28 188 189 I-clinical_variable
AST 28 31 189 192 I-clinical_variable
) 31 32 192 193 I-clinical_variable
and/or 33 39 194 200 O
ALT 40 43 201 204 B-clinical_variable
> 44 45 205 206 O
2.0 46 49 207 210 B-lower_bound
× 50 51 211 212 I-lower_bound
upper 52 57 213 218 I-lower_bound
limit 58 63 219 224 I-lower_bound
of 64 66 225 227 I-lower_bound
normal 67 73 228 234 I-lower_bound
( 74 75 235 236 I-lower_bound
ULN 75 78 236 239 I-lower_bound
) 78 79 239 240 I-lower_bound

Chronic 0 7 241 248 O
treatment 8 17 249 258 O
with 18 22 259 263 O
the 23 26 264 267 O
following 27 36 268 277 O
drugs 37 42 278 283 O
( 43 44 284 285 O
within 44 50 285 291 O
4 51 52 292 293 B-upper_bound
weeks 53 58 294 299 I-upper_bound
of 59 61 300 302 O
study 62 67 303 308 O
entry 68 73 309 314 O
and 74 77 315 318 O
during 78 84 319 325 O
the 85 88 326 329 O
study 89 94 330 335 O
) 94 95 335 336 O

Chronic 0 7 337 344 O
use 8 11 345 348 O
of 12 14 349 351 O
N 15 16 352 353 B-clinical_variable
- 16 17 353 354 I-clinical_variable
acetylcysteine 17 31 354 368 I-clinical_variable
prescribed 32 42 369 379 O
for 43 46 380 383 O
IPF 47 50 384 387 B-chronic_disease
( 51 52 388 389 O
> 52 53 389 390 O
600 54 57 391 394 B-lower_bound
mg 58 60 395 397 I-lower_bound
/ 60 61 397 398 I-lower_bound
day 61 64 398 401 I-lower_bound
) 64 65 401 402 O

Diffusing 0 9 403 412 B-clinical_variable
capacity 10 18 413 421 I-clinical_variable
of 19 21 422 424 I-clinical_variable
the 22 25 425 428 I-clinical_variable
lung 26 30 429 433 I-clinical_variable
for 31 34 434 437 I-clinical_variable
carbon 35 41 438 444 I-clinical_variable
monoxide 42 50 445 453 I-clinical_variable
( 51 52 454 455 I-clinical_variable
DLCO 52 56 455 459 I-clinical_variable
) 56 57 459 460 I-clinical_variable
< 58 59 461 462 O
30 60 62 463 465 B-upper_bound
% 62 63 465 466 I-upper_bound
predicted 64 73 467 476 O

Documented 0 10 477 487 O
sustained 11 20 488 497 O
improvement 21 32 498 509 O
of 33 35 510 512 O
the 36 39 513 516 O
subject 40 47 517 524 O
's 47 49 524 526 O
IPF 50 53 527 530 B-chronic_disease
condition 54 63 531 540 I-chronic_disease
up 64 66 541 543 O
to 67 69 544 546 O
12 70 72 547 549 B-upper_bound
months 73 79 550 556 I-upper_bound
before 80 86 557 563 O
study 87 92 564 569 O
entry 93 98 570 575 O
with 99 103 576 580 O
or 104 106 581 583 O
without 107 114 584 591 O
IPF 115 118 592 595 O
- 118 119 595 596 O
specific 119 127 596 604 O
therapy 128 135 605 612 B-treatment

Effective 0 9 613 622 O
barrier 10 17 623 630 O
methods 18 25 631 638 O
are 26 29 639 642 O
male 30 34 643 647 B-gender
or 35 37 648 650 O
female 38 44 651 657 B-gender
condoms 45 52 658 665 O
, 52 53 665 666 O
diaphragms 54 64 667 677 O
, 64 65 677 678 O
and 66 69 679 682 O
spermicides 70 81 683 694 O
( 82 83 695 696 O
creams 83 89 696 702 O
or 90 92 703 705 O
gels 93 97 706 710 O
that 98 102 711 715 O
contain 103 110 716 723 O
a 111 112 724 725 O
chemical 113 121 726 734 O
to 122 124 735 737 O
kill 125 129 738 742 O
sperm 130 135 743 748 O
) 135 136 748 749 O
; 136 137 749 750 O
or 138 140 751 753 O
( 141 142 754 755 O
d 142 143 755 756 O
) 143 144 756 757 O
vasectomy 145 154 758 767 B-treatment

Effective 0 9 768 777 O
birth 10 15 778 783 O
control 16 23 784 791 O
includes 24 32 792 800 O
( 33 34 801 802 O
a 34 35 802 803 O
) 35 36 803 804 O
intrauterine 37 49 805 817 O
device 50 56 818 824 O
( 57 58 825 826 O
IUD 58 61 826 829 O
) 61 62 829 830 O
plus 63 67 831 835 O
1 68 69 836 837 O
barrier 70 77 838 845 O
method 78 84 846 852 O
; 84 85 852 853 O
( 86 87 854 855 O
b 87 88 855 856 O
) 88 89 856 857 O
stable 90 96 858 864 O
doses 97 102 865 870 O
of 103 105 871 873 O
hormonal 106 114 874 882 O
contraception 115 128 883 896 O
for 129 132 897 900 O
at 133 135 901 903 O
least 136 141 904 909 O
3 142 143 910 911 B-lower_bound
months 144 150 912 918 I-lower_bound
( 151 152 919 920 O
eg 152 154 920 922 O
, 154 155 922 923 O
oral 156 160 924 928 O
, 160 161 928 929 O
injectable 162 172 930 940 O
, 172 173 940 941 O
implant 174 181 942 949 O
, 181 182 949 950 O
transdermal 183 194 951 962 O
) 194 195 962 963 O
plus 196 200 964 968 O
1 201 202 969 970 O
barrier 203 210 971 978 O
method 211 217 979 985 O
; 217 218 985 986 O
( 219 220 987 988 O
c 220 221 988 989 O
) 221 222 989 990 O
2 223 224 991 992 O
barrier 225 232 993 1000 O
methods 233 240 1001 1008 O

FVC 0 3 1009 1012 B-clinical_variable
% 4 5 1013 1014 O
≥ 6 7 1015 1016 O
50 8 10 1017 1019 B-lower_bound
% 10 11 1019 1020 I-lower_bound
normal 12 18 1021 1027 O
predicted 19 28 1028 1037 O
value 29 34 1038 1043 O

Has 0 3 1044 1047 O
either 4 10 1048 1054 O
received 11 19 1055 1063 O
pirfenidone 20 31 1064 1075 B-treatment
and/or 32 38 1076 1082 O
nintedanib 39 49 1083 1093 B-treatment
or 50 52 1094 1096 O
has 53 56 1097 1100 O
been 57 61 1101 1105 O
offered 62 69 1106 1113 O
both 70 74 1114 1118 O
treatments 75 85 1119 1129 B-treatment
( 86 87 1130 1131 O
with 87 91 1131 1135 O
last 92 96 1136 1140 O
dose 97 101 1141 1145 O
administered 102 114 1146 1158 O
at 115 117 1159 1161 O
least 118 123 1162 1167 O
1 124 125 1168 1169 B-lower_bound
month 126 131 1170 1175 I-lower_bound
before 132 138 1176 1182 O
the 139 142 1183 1186 O
expected 143 151 1187 1195 O
start 152 157 1196 1201 O
of 158 160 1202 1204 O
study 161 166 1205 1210 O
drug 167 171 1211 1215 O
dosing 172 178 1216 1222 O
) 178 179 1222 1223 O

Hemoglobin 0 10 1224 1234 B-clinical_variable
> 11 12 1235 1236 O
9.0 13 16 1237 1240 B-lower_bound
g 17 18 1241 1242 I-lower_bound
/ 18 19 1242 1243 I-lower_bound
L 19 20 1243 1244 I-lower_bound

If 0 2 1245 1247 O
either 3 9 1248 1254 O
or 10 12 1255 1257 O
both 13 17 1258 1262 O
pirfenidone 18 29 1263 1274 B-treatment
and 30 33 1275 1278 O
nintedanib 34 44 1279 1289 B-treatment
treatment 45 54 1290 1299 I-treatment
has 55 58 1300 1303 O
not 59 62 1304 1307 O
been 63 67 1308 1312 O
given 68 73 1313 1318 O
, 73 74 1318 1319 O
then 75 79 1320 1324 O
documentation 80 93 1325 1338 O
that 94 98 1339 1343 O
the 99 102 1344 1347 O
patient 103 110 1348 1355 O
was 111 114 1356 1359 O
offered 115 122 1360 1367 O
both 123 127 1368 1372 O
treatments 128 138 1373 1383 B-treatment
must 139 143 1384 1388 O
be 144 146 1389 1391 O
documented 147 157 1392 1402 O

Immunosuppressive 0 17 1403 1420 B-treatment
or 18 20 1421 1423 O
cytotoxic 21 30 1424 1433 B-treatment
drugs 31 36 1434 1439 I-treatment
including 37 46 1440 1449 O
cyclophosphamide 47 63 1450 1466 B-treatment
and 64 67 1467 1470 O
azathioprine 68 80 1471 1483 B-treatment

In 0 2 1484 1486 O
the 3 6 1487 1490 O
absence 7 14 1491 1498 O
of 15 17 1499 1501 O
a 18 19 1502 1503 O
surgical 20 28 1504 1512 B-treatment
lung 29 33 1513 1517 I-treatment
biopsy 34 40 1518 1524 I-treatment
, 40 41 1524 1525 O
HRCT 42 46 1526 1530 O
must 47 51 1531 1535 O
be 52 54 1536 1538 O
consistent 55 65 1539 1549 O
with 66 70 1550 1554 O
usual 71 76 1555 1560 O
interstitial 77 89 1561 1573 B-chronic_disease
pneumonitis 90 101 1574 1585 I-chronic_disease

Interstitial 0 12 1586 1598 B-chronic_disease
lung 13 17 1599 1603 I-chronic_disease
disease 18 25 1604 1611 I-chronic_disease
caused 26 32 1612 1618 O
by 33 35 1619 1621 O
conditions 36 46 1622 1632 O
other 47 52 1633 1638 O
than 53 57 1639 1643 O
IPF 58 61 1644 1647 B-chronic_disease

Men 0 3 1648 1651 B-gender
whose 4 9 1652 1657 O
partner 10 17 1658 1665 O
is 18 20 1666 1668 O
pregnant 21 29 1669 1677 B-pregnancy

Men 0 3 1678 1681 B-gender
with 4 8 1682 1686 O
partners 9 17 1687 1695 O
of 18 20 1696 1698 O
childbearing 21 33 1699 1711 O
potential 34 43 1712 1721 O
must 44 48 1722 1726 O
be 49 51 1727 1729 O
willing 52 59 1730 1737 B-contraception_consent
to 60 62 1738 1740 I-contraception_consent
use 63 66 1741 1744 I-contraception_consent
2 67 68 1745 1746 I-contraception_consent
medically 69 78 1747 1756 I-contraception_consent
acceptable 79 89 1757 1767 I-contraception_consent
methods 90 97 1768 1775 I-contraception_consent
of 98 100 1776 1778 I-contraception_consent
contraception 101 114 1779 1792 I-contraception_consent
during 115 121 1793 1799 O
the 122 125 1800 1803 O
trial 126 131 1804 1809 O
and 132 135 1810 1813 O
for 136 139 1814 1817 O
3 140 141 1818 1819 B-upper_bound
months 142 148 1820 1826 I-upper_bound
after 149 154 1827 1832 O
the 155 158 1833 1836 O
last 159 163 1837 1841 O
dose 164 168 1842 1846 O
of 169 171 1847 1849 O
study 172 177 1850 1855 O
drug 178 182 1856 1860 O

Obstructive 0 11 1861 1872 B-chronic_disease
lung 12 16 1873 1877 I-chronic_disease
disease 17 24 1878 1885 I-chronic_disease
: 24 25 1885 1886 O
FEV1/ 26 31 1887 1892 B-clinical_variable
FVC 32 35 1893 1896 I-clinical_variable
ratio 36 41 1897 1902 I-clinical_variable
< 42 43 1903 1904 O
0.70 44 48 1905 1909 B-upper_bound

Oral 0 4 1910 1914 B-treatment
anticoagulants 5 19 1915 1929 I-treatment
prescribed 20 30 1930 1940 O
for 31 34 1941 1944 O
IPF 35 38 1945 1948 B-chronic_disease

Planned 0 7 1949 1956 B-treatment
treatment 8 17 1957 1966 I-treatment
, 17 18 1966 1967 O
or 19 21 1968 1970 O
treatment 22 31 1971 1980 B-treatment
with 32 36 1981 1985 I-treatment
another 37 44 1986 1993 I-treatment
investigational 45 60 1994 2009 I-treatment
drug 61 65 2010 2014 I-treatment
within 66 72 2015 2021 O
4 73 74 2022 2023 B-upper_bound
weeks 75 80 2024 2029 I-upper_bound
before 81 87 2030 2036 O
study 88 93 2037 2042 O
entry 94 99 2043 2048 O

Platelets 0 9 2049 2058 B-clinical_variable
> 10 11 2059 2060 O
100,000 12 19 2061 2068 B-lower_bound
/ 19 20 2068 2069 I-lower_bound
mm3 20 23 2069 2072 I-lower_bound

Previous 0 8 2073 2081 O
exposure 9 17 2082 2090 O
to 18 20 2091 2093 O
KD025 21 26 2094 2099 B-allergy_name
or 27 29 2100 2102 O
known 30 35 2103 2108 O
allergy 36 43 2109 2116 O
/ 43 44 2116 2117 O
sensitivity 44 55 2117 2128 O
to 56 58 2129 2131 O
KD025 59 64 2132 2137 O
or 65 67 2138 2140 O
any 68 71 2141 2144 O
other 72 77 2145 2150 O
ROCK2 78 83 2151 2156 B-allergy_name
inhibitor 84 93 2157 2166 I-allergy_name

Resting 0 7 2167 2174 O
state 8 13 2175 2180 O
SpO2 14 18 2181 2185 B-clinical_variable
≥ 19 20 2186 2187 O
88 21 23 2188 2190 B-lower_bound
% 23 24 2190 2191 I-lower_bound
with 25 29 2192 2196 O
or 30 32 2197 2199 O
without 33 40 2200 2207 O
supplemental 41 53 2208 2220 O
oxygen 54 60 2221 2227 O

Severe 0 6 2228 2234 B-chronic_disease
concomitant 7 18 2235 2246 I-chronic_disease
illness 19 26 2247 2254 I-chronic_disease
limiting 27 35 2255 2263 O
life 36 40 2264 2268 B-clinical_variable
expectancy 41 51 2269 2279 I-clinical_variable
( 52 53 2280 2281 O
< 53 54 2281 2282 O
1 55 56 2283 2284 B-upper_bound
year 57 61 2285 2289 I-upper_bound
) 61 62 2289 2290 O

Systemic 0 8 2291 2299 B-treatment
treatment 9 18 2300 2309 I-treatment
within 19 25 2310 2316 O
4 26 27 2317 2318 B-upper_bound
weeks 28 33 2319 2324 I-upper_bound
before 34 40 2325 2331 O
study 41 46 2332 2337 O
entry 47 52 2338 2343 O
with 53 57 2344 2348 O
cyclosporine 58 70 2349 2361 B-treatment
A 71 72 2362 2363 I-treatment
or 73 75 2364 2366 O
tacrolimus 76 86 2367 2377 B-treatment
, 86 87 2377 2378 O
everolimus 88 98 2379 2389 B-treatment
, 98 99 2389 2390 O
or 100 102 2391 2393 O
sirolimus 103 112 2394 2403 B-treatment
( 113 114 2404 2405 O
calcineurin 114 125 2405 2416 O
or 126 128 2417 2419 O
mammalian 129 138 2420 2429 O
target 139 145 2430 2436 O
of 146 148 2437 2439 O
rapamycin 149 158 2440 2449 O
inhibitors 159 169 2450 2460 O
) 169 170 2460 2461 O

Systolic 0 8 2462 2470 B-clinical_variable
blood 9 14 2471 2476 I-clinical_variable
pressure 15 23 2477 2485 I-clinical_variable
< 24 25 2486 2487 O
100 26 29 2488 2491 B-upper_bound
mmHg 30 34 2492 2496 I-upper_bound

Treatment 0 9 2497 2506 O
with 10 14 2507 2511 O
endothelin 15 25 2512 2522 B-treatment
receptor 26 34 2523 2531 I-treatment
antagonists 35 46 2532 2543 I-treatment
within 47 53 2544 2550 O
4 54 55 2551 2552 B-upper_bound
weeks 56 61 2553 2558 I-upper_bound
before 62 68 2559 2565 O
study 69 74 2566 2571 O
entry 75 80 2572 2577 O

female 0 6 2578 2584 B-gender

postmenopausal 0 14 2585 2599 O
/ 14 15 2599 2600 O
surgically 15 25 2600 2610 O
sterilized 26 36 2611 2621 O
female 37 43 2622 2628 B-gender
subjects 44 52 2629 2637 I-gender

surgically 0 10 2638 2648 O
sterilized 11 21 2649 2659 O
[ 22 23 2660 2661 O
ie 23 25 2661 2663 O
, 25 26 2663 2664 O
total 27 32 2665 2670 B-treatment
hysterectomy 33 45 2671 2683 I-treatment
, 45 46 2683 2684 O
or 47 49 2685 2687 O
bilateral 50 59 2688 2697 B-treatment
salpingo 60 68 2698 2706 I-treatment
- 68 69 2706 2707 I-treatment
oophorectomy 69 81 2707 2719 I-treatment

